Phase II trial of 177 Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC) Meeting Abstract

  

Authors:	Tagawa, S. T.; Milowsky, M. I.; Morris, M. J.; Vallabhajosula, S.; Goldsmith, S.; Matulich, D.; Kaplan, J.; Berger, F.; Scher, H. I.; Bander, N. H.; Nanus, D. M.
Abstract Title:	Phase II trial of 177 Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC)
Meeting Title:	44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	26
Issue:	15 Suppl.
Meeting Dates:	2008 May 30-Jun 3
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2008-05-20
Start Page:	284s
Language:	English
ACCESSION:	WOS:000208457401895
PROVIDER:	wos
DOI:	10.1200/jco.2008.26.15_suppl.5140
Notes:	Meeting Abstract: 5140 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/129786